Arakis and Vectura announce start of phase IIb trial of NVA237 for COPD
Arakis Ltd. , a wholly-owned subsidiary of Sosei Co. Ltd. , and Vectura Group plc announced that their collaborative product, NVA237 (formerly AD 237), a novel inhaled once daily treatment for chronic obstructive pulmonary disease (COPD), has entered a Phase IIb multiple dose-ranging clinical trial. NVA237 is being developed and commercialised by Novartis both as a monotherapy and in combination with their once daily bronchodilator indacaterol (QAB149), under the terms of the agreement signed in April 2005.
The study is a randomised, double-blind, multi-centre, placebo-controlled trial designed to evaluate the efficacy, safety and dose response of NVA237 in patients diagnosed with COPD over a four week period.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.